Having trouble accessing articles? Reset your cache.

BMN-701: Phase I/II data

Data from 16 evaluable patients in the highest dose cohort of the open-label, international Phase I/II POM-001 trial showed that 3 patients receiving 20 mg/kg BMN-701 every 2 weeks

Read the full 298 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE